Oxurion Past Earnings Performance

Past criteria checks 0/6

Oxurion has been growing earnings at an average annual rate of 20.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 50.1% per year.

Key information

20.1%

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-50.1%
Return on equityn/a
Net Margin-13,539.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Oxurion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:TG40 Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-1136
31 Mar 240-1538
31 Dec 230-19410
30 Sep 230-23411
30 Jun 231-28512
31 Mar 231-30614
31 Dec 221-32716
30 Sep 221-30818
30 Jun 221-28819
31 Mar 221-28820
31 Dec 211-29821
30 Sep 211-30922
30 Jun 211-31923
31 Mar 212-29923
31 Dec 202-28922
30 Sep 203-301023
30 Jun 203-321124
31 Mar 204-421225
31 Dec 194-521326
30 Sep 194-541427
30 Jun 193-571428
31 Mar 194-481329
31 Dec 185-381330
30 Sep 186-81228
30 Jun 187231126
31 Mar 186231125
31 Dec 176231023
30 Sep 176-191023
30 Jun 176-611123
31 Mar 176-601124
31 Dec 167-601125
30 Sep 168-471424
30 Jun 169-341723
31 Mar 1610-362122
31 Dec 1511-382621
30 Sep 1512-423021
30 Jun 1513-463421
31 Mar 1513-493722
31 Dec 1414-513923
30 Sep 1415-524024
30 Jun 1417-524126
31 Mar 1465-134529
31 Dec 13113264932

Quality Earnings: TG40 is currently unprofitable.

Growing Profit Margin: TG40 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: TG40 is unprofitable, but has reduced losses over the past 5 years at a rate of 20.1% per year.

Accelerating Growth: Unable to compare TG40's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TG40 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: TG40's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies